John Fesko, President and Chief Business Officer of Natera, Inc. (NASDAQ:NTRA), a $22.1 billion market cap company that has delivered an impressive 159% return over the past year according to InvestingPro, recently sold shares of the company’s stock valued at approximately $3.5 million, according to a recent SEC filing. The transactions, which occurred on January 22, involved the sale of 21,228 shares at prices ranging from $164.9488 to $171.9617 per share. Following these sales, Fesko retains ownership of 147,230 shares in the medical laboratory services company. The sales were made to satisfy tax withholding obligations related to the vesting of restricted stock units. The company has shown strong momentum with a 64% price gain over the past six months, and maintains a GOOD overall financial health rating. For comprehensive insider trading analysis and 11 additional key ProTips, visit InvestingPro.
In other recent news, genetic testing company Natera Inc . has seen several significant developments. Barclays (LON:BARC) has upgraded Natera’s stock rating to Overweight with a $200 price target, citing the company’s successful expansion into new markets. Natera’s evolution from non-NGS-based NIPT focus to becoming a leading player in the NIPT market was highlighted by Barclays’ analyst, Luke Sergott. The company has also extended its portfolio to include NGS-based Oncology and Organ Health testing, contributing to a revenue growth of nearly 55% over the last twelve months.
Natera has also broadened its patent infringement litigation against NeoGenomics (NASDAQ:NEO), involving the RaDaR assay. TD Cowen has reiterated a Buy rating on Natera shares, raising the price target from $175 to $195, reflecting confidence in the company’s future performance. This follows a recent investor dinner with Natera’s CFO, Mike Brophy, where management communicated a highly positive stance on the prospects of Signatera, the company’s specialized test for molecular residual disease (MRD).
Furthermore, Natera has amended an agreement with Dr. Rabinowitz, the Executive Chairman, for him to continue his role under certain conditions. Despite facing a setback in a false advertising lawsuit against Guardant Health (NASDAQ:GH), Natera plans to request the court to overturn the ruling. These developments reflect confidence in the company’s operational success and growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.